Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

Not Applicable

Not yet recruiting

• Conditions: Amyloid Cardiomyopathy
• Interventions: Drug: Enavogliflozin 0.3mg; Drug: Placebo

• Registration Number: NCT07240844
• Lead Sponsor: Seoul St. Mary's Hospital

Brief Summary

This study aims to evaluate the safety and effectiveness of Enavogliflozin 0.3 mg, an SGLT2 inhibitor, in patients with amyloid cardiomyopathy. Participants will take both the study drug and a placebo in two separate periods, with a wash-out period in between. The goal is to determine whether Enavogliflozin is safe and effective for treating amyloid cardiomyopathy.

Detailed Description

Patients with a confirmed diagnosis of cardiac amyloidosis and symptomatic heart failure (NYHA class II-III) will be recruited.

Participants will be randomized to receive either the study drug or placebo and will undergo baseline and 12-week assessments, including the Kansas City Cardiomyopathy Questionnaire (KCCQ), 6-minute walk test, and cardiopulmonary exercise testing. Following a 4-week washout period, participants will cross over to the alternate treatment arm (study drug or placebo) and repeat the same assessments at baseline and 12 weeks.

The primary endpoint will be the change in KCCQ Clinical Summary Score (KCCQ-CSS).

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-09-28
• Study First Submitted QC: 2025-11-20
• Last Update Submitted: 2025-11-20
• Study First Posted: 2025-11-21
• Last Update Posted: 2025-11-21
• Study Start: 2025-11-24
• Primary Completion: 2027-04-29
• Study Completion: 2027-05-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

1. Adults aged 19 years or older
2. Diagnosed with amyloid cardiomyopathy confirmed by cardiac biopsy or non-invasive imaging
3. Presence of heart failure symptoms corresponding to NYHA functional class II-III
4. Patients on stable oral diuretic use, without dose changes exceeding 50% of the previous dose, for at least 2 weeks prior to study enrollment
5. Ambulatory (able to walk)
6. Able to provide written informed consent for study participation

Exclusion Criteria

1. Pregnant or breastfeeding women
2. Active infection
3. Major cardiovascular events (e.g., myocardial infarction, stroke) within the past 6 months
4. Scheduled for coronary revascularization, CRT-D implantation, atrial flutter/fibrillation ablation, or valve surgery
5. History of heart transplantation
6. Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² (calculated by CKD-EPI formula)
7. No history of cancer within the past 5 years at screening (except borderline cancers without recurrence for 2-3 years; multiple myeloma with cardiac involvement is classified as cardiac amyloidosis and is exempt)
8. Heart failure primarily caused by severe left sided valvular disease or ischemic heart disease (except if valvular disease is corrected)
9. Type 1 diabetes mellitus or insulin-dependent diabetes
10. History of ketoacidosis, complicated urinary or genital infections, or kidney stones
11. Systolic blood pressure < 80 mmHg or symptomatic hypotension
12. Major surgery within 90 days prior to enrollment
13. Known hypersensitivity or allergic reaction to the study drug or its components
14. Moderate to severe liver impairment
15. Chronic alcohol or substance abuse
16. Residing in long-term care facilities (e.g., nursing homes)
17. Unable to understand or comply with study drug, procedures, or follow-up, or who are deemed by the investigator to be unlikely to complete the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Enavogliflozin	Enavogliflozin 0.3mg	Administer Enavogliflozin 0.3 mg
Placebo	Placebo	Administer placebo

Primary Outcome Measures

Name	Time	Method
Change in KCCQ-CSS from baseline to Week 12	Baseline and Week 12	Change in the Clinical Summary Score of the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) from baseline to 12 weeks after treatment initiation.; The KCCQ-CSS is a patient-reported outcome measure that assesses symptom frequency and physical limitation in patients with heart failure.; Scores range from 0 to 100, with higher scores indicating better symptom status and physical function (i.e., better health status).; A higher change from baseline reflects an improvement in clinical status.

Secondary Outcome Measures

Name	Time	Method
Change in 6-Minute Walk Distance	Baseline and Week 12	Change in distance walked in 6 minutes from baseline to Week 12. Higher distance indicates better exercise capacity.
Incidence of Worsening Heart Failure Events or Death	From baseline to Week 12 during each treatment period (excluding the 4-week washout period)	Occurrence of worsening heart failure events (defined as emergency outpatient visit or unplanned hospitalization due to heart failure) or death
Change in log-transformed NT-proBNP levels	Baseline and Week 12	Change in log-transformed NT-proBNP levels after 12 weeks of treatment compared to baseline
Change in Body Weight	Baseline and Week 12	Change in body weight in kilograms from baseline to Week 12
Change in Body Fat Percentage	Baseline and Week 12	Change in body fat percentage from baseline to Week 12
Change in Extracellular Water Ratio	Baseline and Week 12	Change in the ratio of extracellular water to total body water from baseline to Week 12

Trial Locations

Locations (2)

Samsung Medical Center; 🇰🇷 Seoul, South Korea

Seoul St. Mary's Hospital, The Catholic University of Korea; 🇰🇷 Seoul, South Korea